Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
复制标题
DOI：
10.3390/ijms23031096
复制
发表时间：
2022-01-20
影响因子：
5.6
通讯作者：
Tsuchiya H
中科院分区：
文献类型：
--
作者：
Miwa S;Yamamoto N;Hayashi K;Takeuchi A;Igarashi K;Tsuchiya H
软骨肉瘤对标准抗癌药物产生耐药性，使其难以控制无法切除或转移的软骨肉瘤。为了改善软骨肉瘤的临床疗效，需要新的治疗方法，如分子靶向药物和免疫治疗。最近的研究揭示了软骨肉瘤的有前景的生物标志物和治疗靶点。此外，几种分子靶向剂在包括软骨肉瘤在内的晚期肉瘤患者的几项临床研究中显示出良好的抗肿瘤活性。本文综述了近年来有关生物标志物和治疗靶点的基础研究以及治疗软骨肉瘤的临床研究进展。由于对标准抗癌药物的耐药性，转移性或无法切除的软骨肉瘤患者的病情进展很难控制。需要新的治疗方法，如分子靶向药物和免疫治疗，以改善晚期软骨肉瘤患者的临床结果。最近的研究已经提出了几个有前景的软骨肉瘤生物标志物和治疗靶点，包括IDH1/2和COL2A1。几种分子靶向药物和免疫疗法在晚期软骨肉瘤患者的临床研究中显示出良好的抗肿瘤活性。本文就生物标志物和分子靶点的基础研究以及软骨肉瘤治疗的临床研究进展作一综述。
Chondrosarcomas develop chemoresistance to standard anticancer drugs, making it difficult to control unresectable or metastatic chondrosarcomas. To improve the clinical outcomes of chondrosarcoma, new treatment approaches, such as molecule-targeting agents and immunotherapy, are needed. Recent research has revealed promising biomarkers and therapeutic targets for chondrosarcoma. In addition, several molecule-targeting agents have shown favorable antitumor activities in several clinical studies in patients with advanced sarcomas, including chondrosarcoma. This review summarizes recent basic studies on biomarkers and therapeutic targets and recent clinical studies on treating chondrosarcomas. Due to resistance to standard anticancer agents, it is difficult to control the disease progression in patients with metastatic or unresectable chondrosarcoma. Novel therapeutic approaches, such as molecule-targeting drugs and immunotherapy, are required to improve clinical outcomes in patients with advanced chondrosarcoma. Recent studies have suggested several promising biomarkers and therapeutic targets for chondrosarcoma, including IDH1/2 and COL2A1. Several molecule-targeting agents and immunotherapies have shown favorable antitumor activity in clinical studies in patients with advanced chondrosarcomas. This review summarizes recent basic studies on biomarkers and molecular targets and recent clinical studies on the treatment of chondrosarcomas.
登录
查看更多内容
影响因子：
64.8
作者：
通讯作者：
--
影响因子：
17.1
作者：
Highfill SL;Cui Y;Giles AJ;Smith JP;Zhang H;Morse E;Kaplan RN;Mackall CL
通讯作者：
Mackall CL
影响因子：
8.4
作者：
Duffaud, Florence;Italiano, Antoine;Blay, Jean-Yves
通讯作者：
Blay, Jean-Yves
软骨肉瘤和过氧化物酶体增殖物激活受体。
影响因子：
2.9
作者：
Nishida K;Kunisada T;Shen ZN;Kadota Y;Hashizume K;Ozaki T
通讯作者：
Ozaki T
影响因子：
--
作者：
Kim MJ;Cho KJ;Ayala AG;Ro JY
通讯作者：
Ro JY